Mepro Pharma


Royal Distribution


ESTI Pharma
Concise Prescribing Info
Pneumonia & nosocomial pneumonia; UTI & intra-abdominal infections; gynaecological infections eg, endometritis & pelvic inflammatory disease; bacterial meningitis; septicaemia. Empiric treatment for presumed infections in patients w/ febrile neutropenia used as monotherapy or in combination w/ antiviral or antifungal agents.
Dosage/Direction for Use
IV As an IV bolus inj over approx 5 min or IV infusion over approx 15-30 min. Adult Pneumonia, UTI, gynaecological infections eg, endometritis 500 mg 8 hrly. Hospital-acquired pneumonia, peritonitis, presumed infections in febrile neutropenic patients, septicaemia 1 g 8 hrly. Meningitis 2 g 8 hrly. Childn >3 mth & up to 12 yr 10-20 mg/kg 8 hrly depending on type & severity of infection, susceptibility of pathogen & condition of the patient; weighing >50 kg Adult dose. Meningitis 40 mg/kg 8 hrly. Febrile episodes in neutropenic patients 20 mg/kg 8 hrly. Renal impairment: CrCl 26-50 mL/min 1 u dose 12 hrly; 10-25 mL/min ½ u dose 12 hrly; <10 mL/min ½ u dose 24 hrly.
Special Precautions
Hypersensitivity, partial cross-allergenicity between other carbapenems & β-lactams, penicillins & cephalosporins; discontinue use & take appropriate measures if allergic reactions occur. Continuously monitor for possible overgrowth of non susceptible organisms. Not recommended in infections caused by methicillin resistant staphylococci. Pseudomembranous colitis may occur; consider in patients who develop diarrhea. History of GI complaints, particularly colitis. Concurrent use w/ potentially nephrotoxic drugs. Carefully monitor transaminase & bilirubin levels in patient w/ hepatic disease. Pregnancy & lactation. Not recommended in infant <3 mth.
Adverse Reactions
Inflammation, thrombophlebitis, pain at the inj site; rash, pruritus, urticaria; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous colitis; reversible thrombocytopenia, eosinophilia, thrombocytopenia, leucopenia & neutropenia, haemolytic anemia, direct or indirect positive Coombs' test; increased serum bilirubin conc, transaminases, alkaline phosphatase & lactic dehydrogenase; headache, paraesthesiae; oral & vag candidosis. Potentially, erythema multiforme, Stevens-Johnson syndrome & toxic epidermal necrolysis.
Drug Interactions
Inhibited renal excretion, & increased elimination t½ & plasma conc w/ probenecid. May reduce serum valproic acid levels, & reach subtherapeutic levels.
MIMS Class
ATC Classification
J01DH02 - meropenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.
Meromax inj 500 mg
Meromax inj 1 g
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in